Ionis Pharmaceuticals, Inc.

NasdaqGS:IONS Voorraadrapport

Marktkapitalisatie: US$5.6b

Ionis Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Ionis Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 32.9% en 21.9% per jaar. De winst per aandeel zal naar verwachting groeien met 33.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -145.2% zijn.

Belangrijke informatie

32.9%

Groei van de winst

33.5%

Groei van de winst per aandeel

Biotechs winstgroei28.5%
Inkomstengroei21.9%
Toekomstig rendement op eigen vermogen-145.2%
Dekking van analisten

Good

Laatst bijgewerkt18 Nov 2024

Recente toekomstige groei-updates

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24
There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28
Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09
Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Dec 07
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Nov 16
A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Aug 03
Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

May 05
Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Jan 20
Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?

Ionis Pharmaceuticals Looks Good For The Long Term

Oct 19

Ionis plans for new manufacturing site in California to support pipeline

Oct 13

Ionis: 2 Drug Advancements With Potential Firsts

Aug 29

Ionis Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Winst- en omzetgroeiprognoses

NasdaqGS:IONS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026957-429-422-27417
12/31/2025730-553-530-38024
12/31/2024623-516-414-36524
9/30/2024803-359-374-352N/A
6/30/2024813-366-375-346N/A
3/31/2024777-385-345-323N/A
12/31/2023788-366-336-308N/A
9/30/2023615-409-574-541N/A
6/30/2023631-309-493-456N/A
3/31/2023576-329-405-377N/A
12/31/2022587-270-294-274N/A
9/30/20228757110130N/A
6/30/2022849-288298N/A
3/31/2022841-43554N/A
12/31/2021810-291331N/A
9/30/2021661-608-96-75N/A
6/30/2021688-550-59-30N/A
3/31/2021708-495-45-11N/A
12/31/2020729-444-536N/A
9/30/202093394173216N/A
6/30/2020940145165213N/A
3/31/2020959169188230N/A
12/31/20191,123281309346N/A
9/30/2019821433154183N/A
6/30/2019799402154170N/A
3/31/2019752366679697N/A
12/31/2018600277585603N/A
9/30/2018575-41485508N/A
6/30/2018548-38N/A563N/A
3/31/20185439N/A65N/A
12/31/201751419N/A174N/A
9/30/201750742N/A127N/A
6/30/201749952N/A122N/A
3/31/2017426-15N/A86N/A
12/31/2016373-60N/A-112N/A
9/30/2016238-184N/A-123N/A
6/30/2016176-227N/A-111N/A
3/31/2016258-134N/A-12N/A
12/31/2015284-88N/A21N/A
9/30/201531714N/A129N/A
6/30/201531223N/A95N/A
3/31/2015249-24N/A-4N/A
12/31/2014214-39N/A6N/A
9/30/2014172-94N/A-79N/A
6/30/2014151-92N/A-15N/A
3/31/2014132-90N/A42N/A
12/31/2013147-61N/A63N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IONS de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IONS de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IONS de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IONS ( 21.9% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van IONS ( 21.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat IONS binnen 3 jaar verliesgevend zal zijn.


Ontdek groeibedrijven